Persistent use of psychotropic drugs in nursing home residents in Norway by unknown
RESEARCH ARTICLE Open Access
Persistent use of psychotropic drugs in
nursing home residents in Norway
Anne-Sofie Helvik1,2,3*, Jūratė Šaltytė Benth4,5,6, Bei Wu7, Knut Engedal3 and Geir Selbæk3,6,8
Abstract
Background: The prevalence of psychotropic drug (PTD) use in NH residents is high, but few have explored
prevalence and persistency in PTD in NH residents and factors associated with persistency. This at the same time
as we know that risk of side events may be higher with long- term use in older adults. Thus, the aim of this study
was to describe the prevalence and persistence in use of PTD and to explore factors associated with persistence in
use of PTD at two consecutive time points in nursing home (NH) residents.
Methods: We included 1163 NH residents in a 72-month longitudinal study with five assessments. Use of PTD,
neuropsychiatric symptoms (NPS), severity of dementia and physical health were assessed each time.
Results: The prevalence over time and persistent use of antipsychotic drugs, antidepressants, anxiolytics and
sedatives at two consecutive time points were high in residents with and without dementia. There was an
association between greater NPS at the first time point, and persistent use of these drugs, but changes in NPS
between time points, did not explain such use. A longer NH stay increased the odds for persistent use of
antipsychotics.
Conclusion: Psychotropic drugs are frequently used as a long-term treatment among NH residents and are
associated with severity of neuropsychiatric symptoms, but not with severity of dementia. Closer attention should
be paid to follow-up of psychotropic drug treatment, and especially for long –term use of antipsychotics, since the
duration of such treatment should be as short as possible.
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Background
The use of psychotropic drugs in European nursing
homes (NH) is reported to be quite common. The
prevalence of use of any psychotropic drug (PTD) varied
between 42 and 80% in studies published from 2005 to
2013 [1–6] and varied between countries [7, 8]. Among
NH residents with dementia or cognitive impairment,
the prevalence of any PTD use is similar or even higher
than among those with normal cognition (48–90%) [9–
14] and also higher than in community living older
adults with dementia [14]. In NHs in Scandinavia, the
use of any PTD is also high (57–80%) [15–19], especially
in studies that only include residents with dementia
(68–85%) [12, 15, 17, 20, 21].
Over the years there has been an increase in use
of PTD in NH [12, 18, 22–28] except for anti-
psychotic drugs, where a decrease has been observed
in recent years [18, 27, 29, 30]. Thus, the prevalence
of antipsychotic drug use in Scandinavian NH resi-
dents with dementia is among the lowest in Europe
(pooled estimates 24%) [31]. Antidepressants are the
most commonly used PTD in Norwegian NH resi-
dents [16, 18, 22].
Antipsychotic drugs are often used to treat neuro-
psychiatric symptoms, such as aggression, agitation or
psychotic symptoms in NH residents with dementia, al-
though non-pharmacological interventions should be the
first choice of treatment for these symptoms [32, 33].
However, in demanding clinical situations, antipsychotic
drugs may be unavoidable, but there is no evidence that
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long-term use of antipsychotic drugs in the management
of neuropsychiatric symptoms is effective [33]. Older
NH residents with dementia can be withdrawn from
long-term antipsychotics without detrimental effects on
their behavior, but caution is required in residents with
severe neuropsychiatric symptoms [34]. Furthermore,
the duration of antipsychotic drug treatment should be
as short as possible, because of the high risk of side ef-
fects [32], such as more rapid progression of dementia
[9] or cognitive decline [35], higher risk of cerebrovascu-
lar events [36] and increased risk of falling [37]. Use of
antipsychotic drugs is also associated with increased
mortality risk [38]. While the side effects of antipsy-
chotics have received the most attention, studies show
that there are serious short- and long-term side effects
such as falls and fall-related fractures associated with
use of antidepressants and with use of benzodiazepines
[37]. The efficacy of antidepressants on depression in
persons with dementia was not confirmed in a meta-
analysis summarizing many randomized control trials
[39]. A recent study of discontinuation of antidepres-
sants in NH residents with dementia and neuropsychi-
atric symptoms in Norway found that most residents
(85%) tolerated discontinuation [40]. However, when
antidepressants are discontinued in residents with de-
mentia they should be monitored carefully to identify
those with worsening depressive symptoms [40]. Au-
thors who studied retrospectively discontinuation of
long-term use of benzodiazepines in older adults with
and without dementia in care institutions found lim-
ited evidence of adverse outcomes due to discontinu-
ation of benzodiazepines, but close attention should
be paid to the possibility of emergent agitation and in
patients with anxiety caution should be practiced [41].
Discontinuation of long-term use of Benzodiazepines
in older adults without dementia has been found to
increase handgrip strength, balance and cognitive
function [42–44].
Of the approximately 75 studies on PTD in NH facil-
ities published after 2004, only a small fraction have ex-
amined use of PTD in a longitudinal design [21, 45–54].
About half of the longitudinal studies have studied the
prevalence of different types of PTD over time or
persistent use at two time points [21, 45–48, 50, 52], but
very few have studied factors associated with the persist-
ent use of PTD, such as antipsychotic drugs [46, 52], an-
tidepressants, anxiolytics or sedatives. However, as the
risk of side events may be higher with long-term use
[32, 33] and is decreased after discontinuation of PTD in
older adults [34, 55] it is of vital importance to study the
persistent use of PTD and its associated factors.
The aim of this study was to describe the prevalence
and persistence of PTD use and to explore factors asso-
ciated with the persistence in use of PTD at two




This was a 72-month longitudinal study with five assess-
ments. Baseline assessment (A1) took place between
November 2004 and January 2005 [56]. The follow-up
assessments took place after 12, 31 and 52 and
72 months (A2–A5).
Setting and participants
In total, Norway has 40,000 NH places (beds) [57] for a
population of about five million, with about 14%
(700,000) of those aged 65 years or older [58]. The juris-
diction for public health care services lies with local mu-
nicipalities, and local authorities offer social services
(such as housing and home services), in-home nursing
and institutional care (mainly in NHs), and provide both
long- and short-term care and rehabilitation.
This study recruited participants from 26 NHs in 18
municipalities. The selection of small, medium, and large
municipalities was made to obtain a wide variety of NH-
settings in the sample. NH residents with a stay of at
least 14 days were eligible for inclusion, no other inclu-
sion or exclusion criteria were used [56]. In all, 1165 res-
idents were eligible for inclusion and only two declined
to participate.
Measures
Psychotropic drugs were grouped according to the
Anatomical Therapeutic Chemical (ATC) Classification
System into the following groups: antipsychotics (N05A
except lithium), antidepressants (N06A), anxiolytics
(N05B), hypnotics/sedatives (N05C), and anti-dementia
medication (N06D) (yes versus no) [59]. Combination
drugs outside ATC NO5B and NO5Cwere not included.
The information was collected from the medical record
of each resident [56].
Dementia and severity of dementia was assessed using
the Clinical Dementia Rating (CDR) scale, covering six
domains (memory; orientation; judgment and problem
solving; community affairs; home and hobbies; and per-
sonal care) with five response categories (0, 0.5, 1, 2, 3)
[60, 61]. The total score was calculated using an algo-
rithm that gives priority to memory [60]. Residents with
a total score of one or higher were regarded as having
dementia. The cut-off CDR ≥1 in defining dementia has
been found adequate in previous Norwegian and inter-
national studies [62–64]. The categorical scores indicate
the severity of dementia: a CDR score of 1 represents
mild dementia, a CDR score of 2 represents moderate
dementia, and a CDR score of 3 represents severe de-
mentia. The sum-score of the six domains (sum of
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boxes), ranging from zero to 18, can also be used to
measure the severity of dementia, as the categorical and
continuous scores correlate highly ≥ 0.9 [65, 66]. The
Spearman correlation between the categorical CDR
score and the CDR sum of boxes score in the present
study was 0.93. Due to a wider range of values, the CDR
sum of boxes offers important advantages when analyz-
ing the data [66].
We used the CDR score (CDR ≥1) as an indication of
dementia, as it was not possible to perform a standard-
ized dementia work-up for all residents because many
were too frail or mentally impaired to take part in exam-
inations such as CT or MRI. A large number of resi-
dents with a CDR score of 3 could not be tested with
any dementia tests such as the Mini Mental Status
Examination [67] or the Clock Drawing Test [68].
Physical health was assessed using the General
Medical Health Rating (GMHR) scale [69]. This is a
one-item global rating scale with four categories: good,
fairly good, poor, and very poor. The rating was based
on all available information on physical health and use
of drugs. The scale has been used in large studies includ-
ing older people with and without dementia [70] and
has been translated and used in several studies [71, 72].
The Personal Activities of Daily Living (P-ADL) score
was assessed with the Physical Self-Maintenance Scale
(PSMS), including six items, with a total score ranging
from 6 to 30 [73]. High scores indicate a lower level of
functioning.
Neuropsychiatric symptoms (NPS) were assessed
using the Neuropsychiatric Inventory Nursing Home
version (NPI-NH) [74, 75]. The 10-item inventory
covers the following symptoms: delusion, hallucin-
ation, euphoria, agitation/aggression, disinhibition,
irritability/lability, depression/dysphoria, anxiety, ap-
athy/indifference, and aberrant motor behavior (no/
yes). For each symptom, severity (score 1–3) multi-
plied by frequency (score 1–4) provides a score from
zero to 12. Based on a previous principal component
analysis, psychosis (delusions, hallucination), agita-
tion (agitation/aggression, disinhibition, irritability),
and affective (depression, anxiety) sub-syndrome
scores were formed by summing the score of the in-
cluded items [76–79]. The apathy/indifference was
analyzed as a single symptom.
Demographic information such as age, gender, mari-
tal status, and length of stay in the NH at the time
of inclusion was collected from medical records. The
type of unit was also recorded from among the fol-
lowing options: regular units (RU), special care unit
for people with dementia (SCU), rehabilitation unit
(REU), and other units (OU), mainly psychogeriatric
wards. The length of stay in a NH before study inclu-
sion was measured in days.
Procedure
Nurses with extensive clinical experience collected the
data. Prior to data collection, all assessors participated in
a 2-day course on how to apply the standardized ques-
tionnaires. A 1-day training program was carried out
prior to each follow-up assessment. The project leader
(GS) was available for consultation throughout the data
collection period. The nurses collected data from med-
ical records and via a standardized interview with the
residents’ primary caregivers, all of whom were regis-
tered nurses. All assessment scales used were standard
translated Norwegian versions. A pilot study including
41 NH residents was carried out to test inter-rater reli-
ability of CDR prior to the first data collection and the
inter-rater reliability was very good. The kappa statistics
for the global CDR score were 1 (between geriatric
psychiatrist and registered nurse specialized in psych-
iatry) and 0.86 (between geriatric psychiatrist and regis-
tered nurse). More detailed information of the inter-
rating reliability test has been published elsewhere [56].
Study information was given to the residents and their
family members. The residents and their next of kin
were informed that they could refuse to participate at
any stage of the study. This procedure was recom-
mended and approved by the Regional Ethics Committee
in the south east of Norway, the Data Inspectorate and
the Directorate for Health and Social Affairs in 2004 be-
fore data collection.
Data analysis
Sample characteristics at baseline were described as
means and standard deviations (SD) or frequencies and
percentages. Residents with CDR ≥ 1 and CDR < 1 were
compared by Independent samples t-test for continuous
and χ2-test for categorical variables. Prevalence and per-
sistence of PTD use among those with and without de-
mentia were compared by Z-test for proportions. The
persistence in outcomes, use of antipsychotics, antide-
pressants, anxiolytics and sedatives were assessed with a
logistic regression model for hierarchical data (SAS
GLIMMIX procedure). Random effects for type of unit
nested in a NH were included into the model. The
dependent variable was current use of a specific type of
PTD drug, while the independent variable was either use
of the same drug at the previous time point (lag 1), two
time points previously (lag 2) or three time points previ-
ously (lag 3). All models were adjusted for a number of
relevant covariates measured at the same time point as
the independent variable. A similar model was estimated
to assess variables associated to persistent use of drugs,
where the outcome was defined as 1 in the case of use
of drugs at two adjacent time points and 0 otherwise. In
addition, exploratory analyses assessing association be-
tween change in NPI sub-syndromes and persistent use
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of drugs were performed. All multivariate models were
reduced using Akaike’s Information Criteria, where a
lower value means a better model. The results were
tabulated as odds ratios (ORs) with corresponding 95%
confidence intervals (CI) and presented graphically.
All analyses were performed in SPSS version 22 and
SAS v9.3. P-values below 0.05 were considered statically
significant. All tests were two-sided.
Results
Sample characteristics
At baseline, the mean (SD) age of the residents was 84.4
(7.8) years and 846 (72.7%) of them were women
(Table 1). The mean (SD) baseline CDR sum of boxes
was 11.2 (5.3) and 932 (80.1%) residents had CDR ≥ 1 in-
dicating dementia. The mean length of stay at baseline
was 938.3 (1013.1) days and the mean (SD) number of
prescribed drugs taken regularly was 6.0 (3.1). Of the
1163 residents at baseline, 98 (8.4%) were still alive and
available at the fifth follow-up (see Fig. 1). Mean (SD)
time of follow-up was 829.5 (690.0) days.
Prevalence of psychotropic drugs over time
The prevalence of PTD use at baseline and each of the
follow-up time points are presented in Table 2.
Antidepressants were most frequently used (38.3% at
baseline, 32.7% at last follow-up); while anti-dementia
drugs were least frequently used (11.3% at baseline, 0%
at last follow-up). The prevalence of use of any PTD was
high throughout the period; at baseline the prevalence
was 72.9%, but had fallen to 63.3% at the last follow-up.
At baseline, the use of any PTD occurred more fre-
quently in residents with dementia, while at the last
follow-up any PTD was more often used in residents
without dementia. Atypical antipsychotics were used
more frequently in residents with dementia at A1–A3,
whereas residents without dementia used anxiolytics
more frequently at A2 and A3 and sedatives more fre-
quently at A1–A4, respectively.
Persistent use of psychotropic drugs
The proportion of PTD use at two consecutive time
points was high (>50%) throughout the period for all
types of PTD, except for use of anti-dementia drugs
(Table 2). Persistent use of anxiolytics at two consecutive
time points was higher for residents without dementia
than those with dementia. Among those who completed
all assessments (n = 98), 10.4% used antipsychotic drugs,
19.8% used antidepressants, 11.5% used anxiolytics and
9.4% used sedatives at all assessments. Unadjusted and
Table 1 Sample characteristics at baseline
A1 CDR≥ 1 CDR < 1 P-valuesa
1163 932
Socio-demographics
Age Mean (SD) 84.4 (7.8) 84.5 (7.5) 83.8 (9.0) 0.223
Females N (%) 846 (72.7) 686 (73.6) 156 (68.7) 0.139
Education < 10 years N (%) 847 (74.8) 673 (74.1) 170 (76.9) 0.390
























PSMS score Mean (SD) 18.1 (5.4) 18.8 (5.3) 15.4 (4.8) <0.001
NPI Agitation sub-syndrome Mean (SD) 5.8 (8.0) 6.5 (8.2) 2.9 (6.1) <0.001
NPI Psychosis sub-syndrome Mean (SD) 2.8 (5.1) 3.2 (5.3) 1.3 (3.8) <0.001
NPI Affective sub-syndrome Mean (SD) 3.5 (5.3) 3.7 (5.4) 2.9 (4.9) 0.041
NPI Apathy Mean (SD) 2.2 (3.7) 2.4 (3.8) 1.1 (2.9) <0.001
No of drugs Mean (SD) 6.0 (3.1) 5.8 (3.0) 6.9 (3.3) <0.001
Days in NH Mean (SD) 938.3 (1013.0) 928.9 (910.1) 975.5 (1359.3) 0.534
CDR Clinical Dementia Rating scale
GMHR General Medical Health rating
PSMS Physical Self-Maintenance Scale
NPI Neuropsychiatric Inventory
NH Nursing home
aCalculated by using t-test for Independent samples for continuous or χ2-test for categorical variables
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adjusted odds for use of PTD at one time point, given
use of the same type of PTD at an earlier time point was
estimated for all types of PTD except for anti-dementia
drug use (Table 3 and Fig. 2). Both in unadjusted and
adjusted analyses, the odds for persistent use of antipsy-
chotics, antidepressants, anxiolytics and sedative were
high. The odds for persistent use of these PTD were
highest when compared with use at the closest earlier
assessment time point (Lag 1) and fell successively when
the distance between the assessment time points in-
creased (Lags 2 and 3), with one exception for antipsy-
chotics where the odds slightly increased when there
were three time points between assessments (Lag 3)
compared to two time points (Lag 2). All results were
highly significant (p < 0.001).
Factors associated with use of psychotropic drugs at two
consecutive time points
The adjusted risk for persistent use of antipsychotics at
two consecutive time points was elevated when residents
had higher psychosis sub-syndrome score or were youn-
ger, were male or had a longer NH stay at baseline
(Table 4). The adjusted risk for persistent use of antide-
pressants was elevated when residents had higher P-
ADL functioning (lower PSMS score) or higher affective
sub-syndrome score. The adjusted risk for persistent use
of anxiolytics was elevated when residents had higher P-
ADL functioning (lower PSMS score) or higher affective
sub-syndrome score or stayed in a larger NH (Table 5).
The adjusted risk for persistent use of sedatives was ele-
vated when residents had better cognitive functioning
(lower CDR sum of boxes) or higher affective sub-
syndrome score or lower apathy symptom score.
In a subsequent analysis where sub-syndrome scores
of NPS at the first time point were replaced by change
in sub-syndrome score between the two assessments, we
found no association between change in the sub-
syndrome scores of NPS and persistent use of anti-
psychotic drugs, antidepressants, anxiolytics or sedatives.
Discussion
In this Norwegian NH study, the prevalence and persist-
ent use of PTD at two consecutive time points was high,
both for residents with and without dementia, except for
use of an anti-dementia drug. Close to three-quarters of
the dementia and two-thirds of non-dementia residents
used PTD at baseline of the data collection. Persistent
use of anxiolytics was more common in residents with-
out dementia. The persistent use decreased gradually
when the distance between the assessment time points
increased (Lags 2 and 3), with the exception of the use
of antipsychotics drugs. More severe NPS were associ-
ated with persistent use of antipsychotics drugs, antide-
pressants, anxiolytics and sedatives at the next time
point, but change in NPS between the time points was
not associated with persistent use of PTD. Better P-ADL
Fig. 1 Flow chart. Mean (SD) time between accessions were 11.1 (0.5) months for A1–A2, 18.6 (1.3) months for A2–A3, 20.5 (1.7) months for
A3–A4 and 20.8 (2.8) months for A4–A5
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functioning (lower PSMS score) was associated with per-
sistent use of antidepressants and anxiolytics. Further-
more, less severe dementia was associated with persistent
use of sedatives. Of the organizational variables included
in the analysis, we found that a longer stay in NH in-
creased the odds for persistent use of antipsychotics at
two consecutive time points and staying in a larger-sized
NH increased the odds for persistent use of anxiolytics.
Use of antipsychotics
The study found that the prevalence of atypical antipsy-
chotics was higher in residents with dementia than in resi-
dents without, but only for the first three time points. Use
of conventional antipsychotics did not differ between resi-
dents with or without dementia at any time point. The
persistence in use of both atypical and conventional anti-
psychotics at two consecutive time points was high
(>50%) during the entire follow-up period of 72 months
for both groups of residents. A small 6-month follow-up
study of newly arrived NH residents in Australia has
previously reported the persistence of antipsychotics to be
equally high [49]. Given the strong evidence on the in-
creased mortality risk associated with use of conventional
antipsychotics in people with dementia it is rather surpris-
ing to see that they are still used to that extent. These
findings are alarming, since the duration of such treat-
ment should be as short as possible [32]. In the present
adjusted logistic regression analysis for persistent use of
antipsychotic drugs at two consecutive time points, higher
severity of psychosis increased the risk for persistent use
of antipsychotics. However, it is surprising that in the ex-
ploratory analysis, a change in NPS was not associated
with persistent use of antipsychotics. Clinical recommen-
dations have highlighted the need for clinicians to monitor
NPS closely and consider discontinuing treatment with
antipsychotics when an obvious treatment effect does not
occur or the residents have side effects due to the treat-
ment [32]. It could be that people receiving PTD had
more severe symptoms prior to drug initiation. Also, it
could be that antipsychotics were described as unspecific
Table 2 Prevalence and persistence of PTD use according to the presence of dementia at each assessment (%)
Prevalence in percentages













All (n = 209) D/nD
(n = 160/48)
All (n = 98) D/nD
(n = 75/22)
Antipsychotics (AP) 24.1 26.0/15.9*** 25.2 26.4/20.8 20.5 22.0/16.0 20.6 22.5/14.6 20.4 20.0/22.7
Trad. AP 11.3 11.5/11.0 12.2 11.6/14.5 9.4 9.0/10.6 8.6 9.4/6.3 12.2 12.0/13.6
Atypical AP 13.2 14.9/5.7*** 13.8 15.6/6.9*** 11.9 13.7/6.4** 12.6 13.1/8.3 8.2 8.0/9.1
Antidepressants 38.3 39.1/34.8 37.3 37.9/34.0 36.7 35.3/40.4 35.4 33.1/41.7 32.7 29.3/40.9
Anxiolytics 24.2 23.8/26.4 24.2 22.9/29.6* 25.1 21.3/37.2*** 28.7 26.9/35.4 22.4 21.3/27.3
Sedatives 29.0 26.4/39.6*** 26.6 23.4/38.4*** 24.1 21.0/33.0* 23.9 19.4/37.5** 23.5 20.0/31.8
Antidementia drug 11.3 13.5/2.2*** 9.8 11.8/1.9*** 5.3 6.3/2.1* 2.9 3.1/2.1 0 0/0
Any PTD 72.9 74.5/66.5* 71.4 71.5/70.4 70.4 67.7/78.7* 69.4 66.9/77.1 63.3 57.3/81.8**
Persistence at two consecutive time points in percentages
A1–A2 A2–A3 A3–A4 A4–A5
All D/nD All D/nD All D/nD All D/nD
Antipsychotics (AP) 76.7 75.2/88.9* 64.9 67.6/55.0 69.6 67.5/83.3 70.0 68.8/75.0
Trad. AP 73.6 70.8/84.2 61.4 63.3/57.1 73.7 73.3/75.0 80.0 75.0/100
Atypical AP 74.5 74.7/80.0 61.5 63.0/50.0 62.1 59.3/100*** 60.0 62.5/50.0
Antidepressants 80.4 79.8/82.8 76.5 73.1/87.9* 72.2 66.1/89.5** 75.7 76.9/70.0
Anxiolytics 76.9 73.6/89.5** 69.2 62.7/84.4** 86.8 82.1/100** 66.7 66.7/66.7
Sedatives 70.9 65.8/82.8** 64.8 69.1/55.6 69.6 64.9/77.8 68.0 58.8/85.7
Antidementia drug 66.0 65.3/100*** 38.1 36.6/100*** 27.3 27.3/0 0 0/0
Any PTD 89.8 88.7/94.3* 85.3 82.4/94.2** 89.3 86.6/97.3** 78.4 75.5/85.0
A1–A5: Assessment 1–5
D Dementia CDR ≥ 1; nD No dementia CDR < 1
CDR ratings were missing for 4 people at A1, 2 people at A2 and 2 people at A3
CDR Clinical Dementia Rating scale
Trad Conventional
PTD Psychotropic drugs
*p < 0.05, **p ≤ 0.01; ***p ≤ 0.001 (Z-test for proportions used)
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sedatives. Very few studies have examined variables asso-
ciated with persistent use of antipsychotics in NH resi-
dents [46, 52], but none of these studies have explicitly
explored the importance of NPS in the persistent use of
antipsychotic drugs. However, cross-sectional studies have
explored the association between NPS and use of anti-
psychotic drugs and found that higher total symptom load
[80] and more severe psychosis sub-syndromes symptoms
were associated with use of antipsychotics [11, 14, 81, 82].
In the adjusted logistic regression analysis of use of an-
tipsychotics, younger age and male gender increased the
risk for persistent use of antipsychotics. In contrast, a
small Swedish 6-month follow-up study in NH residents
with dementia did not find age, gender or other personal
characteristics of the residents such as P-ADL or cogni-
tive functioning important for persistent use of antipsy-
chotics [52]. Our finding may partly be explained by age
and gender-based expressions of behavioral symptoms
[80] not captured by the NPS. Male and younger
residents may be experienced as more threatening in
their verbal or physical expressions and are physically
stronger compared to women and older residents, and
for this reason may be put on antipsychotic drugs. In
line with our results, cross-sectional studies of use of an-
tipsychotics in NH residents have found that younger
residents [4, 8, 15, 22, 80, 82, 83] and male residents
[5, 80, 84] are more likely to receive antipsychotics.
Persistent use of antipsychotics has been reported to
be more frequent in regular care units than in SCU [46].
In the present study we did not find an association be-
tween the type of care unit and persistent use of antipsy-
chotics. In Norway, SCUs have residents with more
severe NPS than other units, which could explain our re-
sult [30]. However, we found that residents with a longer
stay in NH at baseline had an increased likelihood of
being persistent users of antipsychotics. We do not have
a firm explanation for this, but it may be that newly ar-
rived NH residents receive more attention from the staff
Table 3 Odds ratios for use of each category of psychotropic drugs at one time point given use of the same category of the
psychotropic drug at an earlier time point (the distance between time points is called lag), unadjusted and adjusted analyses where
relevant covariates adjusted for were measured at the same earlier time
Variables Unadjusted Adjusted
OR (95% CI) P-value OR (95% CI) P-value
Lag 1, N = 1406 observations
Antipsychoticsa 30.7 (21.8; 43.1) <0.001 28.8 (20.31; 40.8) <0.001
Antidepressantsb 32.6 (23.8; 44.8) <0.001 34.1 (24.6; 47.4) <0.001
Anxiolyticsc 33.1 (23.7; 46.2) <0.001 32.2 (23.1; 45.0) <0.001
Sedativesd 22.6 (15.6; 30.8) <0.001 23.1 (16.8; 31.7) <0.001
Lag 2, N = 654 observations
Antipsychoticse 13.3 (8.3; 21.4) <0.001 13.5 (8.1; 22.3) <0.001
Antidepressantsf 15.5 (9.9; 24.2) <0.001 16.0 (10.2; 25.3) <0.001
Anxiolyticsg 21.4 (12.8; 35.7) <0.001 23.4 (13.9; 39.6) <0.001
Sedativesh 9.3 (5.9; 14.4) <0.001 9.4 (5.9; 14.8) <0.001
Lag 3, N = 288 observations
Antipsychoticsi 16.5 (7.5; 36.3) <0.001 17.9 (7.5; 42.4) <0.001
Antidepressantsj 10.0 (4.9; 20.4) <0.001 12.6 (5.8; 27.2) <0.001
Anxiolyticsk 14.4 (6.5; 32.1) <0.001 14.3 (7.0; 29.2) <0.001
Sedativesl 7.0 (3.6; 13.9) <0.001 6.4 (3.2; 12.6) <0.001
Lag 1: two consecutive assessment time points
Lag 2: one time point between selected time points
Lag 3: two time points between selected time points
aAdjusted for: PSMS score, NPI Agitation sub-syndrome, NPI Psychosis sub-syndrome, NPI Affective sub-syndrome, NH size age and duration in NH
bAdjusted for: PSMS score, NPI- Affective sub-syndrome, NPI Apathy and duration in NH
cAdjusted for CDR sum of boxes, NPI- Affective sub-syndrome and level of education
dAdjusted for PSMS score, NPI Apathy and duration in NH
eAdjusted for PSMS score, NPI Psychosis sub-syndrome, NPI Apathy, Type of nursing home and age
fAdjusted for: CDR sum of boxes, PSMS score and NPI- Affective sub-syndrome
gAdjusted for CDR sum of boxes, PSMS score and level of education
hAdjusted for CDR sum of boxes, PSMS and age
iAdjusted for PSMS score and age
jAdjusted for: CDR sum of boxes, NPI- Affective sub-syndrome and NPI Apathy
kAdjusted for NPI Agitation sub-syndrome, NPI Psychosis sub-syndrome, NPI Affective sub-syndrome, NPI Apathy, level of education and Type of nursing
home unit
lAdjusted for CDR sum of boxes, NPI Psychosis sub-syndrome and Nursing home size
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or respond better to care that is intended to reduce
stress, strain and symptoms related to dementia.
Use of antidepressants
We found, in line with other studies, that antidepres-
sants were the most frequently used PTD in NH resi-
dents [48, 49] and that the frequency did not differ
between residents with or without dementia [85]. The
persistence of use of antidepressants was also high [49].
As we could expect, those with more severe affective
symptoms had higher odds for persistent use of antide-
pressants. This result is in line with cross-sectional stud-
ies of associations for use of antidepressants [11, 15, 81].
Even so, the efficacy of antidepressants in treating de-
pression in persons with dementia is uncertain. The high
prevalence and persistence of antidepressants use may
indicate that these drugs also are used for the treatment
of agitation. Better performance in P-ADL was more
likely to be associated with persistent antidepressant
users. We do not have a firm explanation for this, but it
may be that those with better P-ADL also have a better
ability to express their emotional state.
Use of anxiolytics, sedatives and anti-dementia drugs
The prevalence of anxiolytics in the NH residents varied
between 20 and 40%, and was significantly higher in res-
idents without dementia, while the persistent use of an-
xiolytics in adjusted analysis was not explained by the
severity of dementia. As for antidepressants, persistent
use of anxiolytics was explained by more severe affective
symptoms and better P-ADL functioning, but not by
change in affective sub-syndrome symptoms between
time points. The size of the NH was associated with per-
sistent use of anxiolytics. We speculate that staff distress
[81], registered nursing hours per resident [86] and
other organizational factors [5] that we have not mea-
sured may be related to NH size, quality of care and use
or persistent use of anxiolytics.
Use of sedatives was higher among residents without
dementia than residents with dementia and varied
between 19 and 26% in residents with dementia and
between 32 and 40% in residents without dementia. A
possible explanation may be that residents without de-
mentia are more vulnerable to disturbances in the NH
environment and at the same time may be more able to
ask for sedatives than residents with dementia.
The prevalence of anti-dementia drugs use was at
baseline 11.3% for all residents and as expected the
prevalence of such use declined at each of the follow-
ups and at the fifth assessment no one used anti-
dementia drugs. At the four first assessment time points
between 1.9 to 2.2% of residents with CDR less than 1
were prescribed anti-dementia drugs. This may indicate
that the NH physicians have prescribed the anti-
dementia drugs without having a dementia diagnosis
(P70), but the physicians may have used the diagnosis
cognitive problems (P20) as an indication for prescribing
the drug. This is quite common in Norway. However, in
a recent Norwegian study it was found that a substantial
number of persons who purchased anti-dementia drugs
Fig. 2 Illustration of OR for use of each category of psychotropic drugs at one time point given use of the same category of psychotropic drug
at an earlier time point by distance (Lag) between the time points, unadjusted and adjusted. a Antipsychotics; b Antidepressants; c Anxiolytics;
and d Sedatives
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had no diagnosis of dementia or cognitive problems
registered in the primary health care service system [87].
Strength and limitations
The study has significant strengths. Firstly, all nurses
participating in the data collection participated in a 2-
day educational course to ensure that they had adequate
knowledge prior to collecting data for this study and
participated in a 1-day educational course before the
follow-up data collections. This ensured high data qual-
ity. Secondly, a large sample size allowed us to adjust for
many potentially important variables, such as health and
demographic factors. Furthermore, this study benefits
from the inclusion of NHs located in a large part of the
country. However, we cannot guarantee that the sample
is representative for Norwegian NH residents since
inclusion was not based on random selection from all
NHs in Norway.
The study has some limitations. Firstly, the data from
the present study is quite old since data collection
started in 2004, and thus, may not represent medication
use patterns in Norwegian NHs of today. Secondly, a
high drop-out rate mainly due to death might have in-
troduced some bias into the results. However, this meth-
odological problem is inherent to most longitudinal NH
studies. Also, we used linear mixed models that include
all available data (data from drop-outs as well) in the
analysis. Due to the low number of participants at the
end of the follow-up period, the analysis of persistence
was limited to three lags only. Thirdly, the time intervals
between the assessments varied somewhat among partic-
ipants. However, this affects the results only minimally,
since the time intervals between assessments were quite
Table 4 Odds of use of Antipsychotics or Antidepressants at one time point given use of Antipsychotics or Antidepressants at the
previous time point, covariates measured at the “previous” time point, N = 1406 observations
Variables Antipsychotics Antidepressants
Unadjusted Adjusted Unadjusted Adjusted
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Assessed at previous time point
CDR sum of boxes 1.04 (1.002; 1.07) 0.036 0.97 (0.95; 0.995) 0.020
GMHR
Good 1.25 (0.66; 2.37) 0.498 0.98 (0.59; 1.63) 0.934 0.63 (0.35; 1.12)3 0.111
Fairly good 1.11 (0.63; 1.98) 0.715 1.29 (0.82; 2.02) 0.273 0.92 (0.56; 1.51)8 0.745
Poor 1.53 (0.86; 2.72) 0.151 1.62 (1.03; 2.56) 0.038 1.34 (0.83; 2.16)5 0.229
Very Poor 1 - 1 - 1 -
PSMS score 1.03 (0.997; 1.06) 0.073 0.96 (0.94; 0.98) 0.001 0.94 (0.91; 0.97)2 <0.001
NPI Agitation sub-syndrome 1.05 (1.03; 1.07) <0.001 1.02 (0.997; 1.04)6 0.093 0.997 (0.98; 1.01) 0.714
NPI Psychosis sub-syndrome 1.09 (1.06; 1.12) <0.001 1.06 (1.03; 1.10)2 0.001 1.00 (0.98; 1.03) 0.915 0.97 (0.95; 1.00)4 0.060
NPI Affective sub-syndrome 1.06 (1.03; 1.09) <0.001 1.03 (0.999; 1.07)5 0.060 1.08 (1.05; 1.10) <0.001 1.08 (1.05; 1.11)1 <0.001
NPI Apathy 1.07 (1.03; 1.12) <0.001 0.99 (0.96; 1.03) 0.732
Assessed at baseline
Age 0.95 (0.93; 0.97) <0.001 0.95 (0.93; 0.97)1 <0.001 0.99 (0.98; 1.01) 0.317 0.98 (0.97; 1.00)6 0.056
Females 0.56 (0.40; 0.80) 0.001 0.64 (0.44; 0.93)4 0.019 1.38 (1.02; 1.87) 0.035 1.33 (0.97; 1.82)7 0.078
Education (<=10 years) 0.97 (0.68; 1.39) 0.865 0.88 (0.66; 1.17) 0.385
Duration in NH (LN) 1.21 (1.06; 1.40) 0.007 1.21 (1.05; 1.40)3 0.011 0.98 (0.88; 1.09) 0.654
Nursing home size 0.998 (0.993; 1.003) 0.382 1.00 (0.998; 1.01) 0.347
Type of nursing home unit
RU 1 - 1 -
REU 0.57 (0.10; 3.41) 0.539 1.03 (0.30; 3.51) 0.959
SCU 1.24 (0.78; 1.97) 0.367 0.80 (0.55; 1.17) 0.248
OU 3.25 (0.63; 16.81) 0.160 1.13 (0.28; 4.61)1 0.865
RU Regular units
REU rehabilitation unit
SCU special care unit for people with dementia
OU other units
The relative importance of each covariate in the adjusted models is included with a number after the 95% CI; lowest number has highest importance
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long and not used in the models explicitly, only as lags.
In the present study the time intervals between the as-
sessments were 1 year or more and due to the study de-
sign, we do not know whether there were changes in
PTD use between assessments.
Fourthly, there is a limitation on the accuracy of
dementia diagnoses, since dementia and degree of
dementia are based on the CDR rating of several assessors
and the fact that a CDR assessment was used, and not a
standardized dementia diagnosis, including neuropsycho-
logical tests. A large number of residents with a CDR
score of 3 could not be tested with any dementia tests
such as the Mini Mental Status Examination or the Clock
Drawing Test. However, CDR is an accepted assessment
tool and is commonly used in epidemiological NH studies
to identify dementia and measure the severity of dementia
[65, 88], and the agreement between CDR and a diagnos-
tic assessment according to the ICD-10 is high [62].
Conclusion
Psychotropic drugs were frequently used as a long-term
treatment among NH residents and were associated with
severity of neuropsychiatric symptoms, but not with se-
verity of dementia. The high prevalence and persistence
of psychotropic drug use may indicate that the treatment
is not in line with current treatment recommendation. It
is important that clinicians monitor effects and side ef-
fects of PTD treatment closely and stop treatment when
the risk is not balanced by considerable benefits to the
NH resident.
Table 5 Odds of use of Anxiolytics or Sedatives or at one time point given use of Anxiolytics or Sedatives at a previous time point,
covariates measured at the “previous” time point, N = 1406 observations
Variables Anxiolytics Sedatives
Unadjusted Adjusted Unadjusted Adjusted
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Assessed at previous time point
CDR sum of boxes 0.96 (0.94; 0.99) 0.015 0.97 (0.94; 1.01)4 0.125 0.94 (0.91; 0.97) <0.001 0.94 (0.91; 0.97)1 <0.001
GMHR
Good 1.31 (0.68; 2.54) 0.421 1.20 (0.65; 2.23)
Fairly good 1.56 (0.87; 2.81) 0.138 1.42 (0.82; 2.47) 0.560
Poor 1.83 (1.01; 3.30) 0.046 1.43 (0.82; 2.49) 0.209
Very Poor 1 - 1 0.212
PSMS score 0.96 (0.93; 0.98) 0.002 0.96 (0.93; 0.99)3 0.016 0.95 (0.93; 0.98) -
NPI Agitation sub-syndrome 1.00 (0.98; 1.02) 0.964 0.99 (0.97; 1.01) 0.001
NPI Psychosis sub-syndrome 1.01 (0.98; 1.04) 0.451 1.00 (0.97; 1.04) 0.358
NPI Affective sub-syndrome 1.08 (1.05; 1.11) <0.001 1.09 (1.06; 1.12)1 <0.001 1.04 (1.01; 1.07) 0.878
0.005
1.06 (1.03; 1.09)2 <0.001
NPI Apathy 1.01 (0.97; 1.05) 0.662 0.94 (0.90; 0.99) 0.012 0.95 (0.90; 0.996)4 0.034
Assessed at baseline
Age 0.997 (0.98; 1.02) 0.775 1.002 (0.98; 1.02) 0.812
Females 1.01 (0.71; 1.44) 0.967 1.28 (0.89; 1.83) 0.182
Education (<=10 years) 1.16 (0.81; 1.66) 0.416 0.82 (0.59; 1.15) 0.253 0.77 (0.54; 1.08)5 0.125
Duration in NH (LN) 1.07 (0.94; 1.22) 0.292 1.12 (0.98; 1.28)5 0.101 0.91 (0.81; 1.04) 0.164
Nursing home size 1.01 (1.002; 1.01) 0.004 1.007 (1.002; 1.011)2 0.002 1.00 (0.999; 1.01) 0.109 1.004 (1.00; 1.008)3 0.072
Type of nursing home unit
RU 1 - 1 -
REU 0.18 (0.02; 1.83) 0.146 2.35 (0.63; 8.79) 0.206
0.754 0.62 (0.39; 0.98) 0.041
SCU 0.93 (0.58; 1.49)
OU 2.96 (0.54; 16.13) 0.209 1.67 (0.34; 8.19) 0.526
RU Regular units
REU rehabilitation unit
SCU special care unit for people with dementia
OU other units
The relative importance of each covariate in the adjusted models is included with a number after the 95% CI; lowest number has highest importance
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